Liquidia (LQDA) Research & Development (2020 - 2026)
Liquidia (LQDA) posted Research & Development of $17.2 million for Q2 2026, up 36.7% on a QoQ basis from $12.6 million in Q1 2026, and up 185.4% year-over-year from $6.0 million in Q2 2025.
Analysis
Liquidia (LQDA) Research & Development (2020 - 2026) Analysis & Trends
Liquidia has reported Research & Development for 7 years, with the latest figure at $17.2 million in Q2 2026.
- On a quarterly basis, Research & Development rose 185.4% year-over-year to $17.2 million in Q2 2026; TTM through Jun 2026 was $56.0 million, a 35.53% increase from a year earlier, with the FY2025 full-year figure at $39.3 million, down 17.9% from the prior year.
- Research & Development was $17.2 million for Q2 2026 at Liquidia, up from $12.6 million in the prior quarter.
- The five-year high for Research & Development was $17.7 million in Q2 2023, with the low at $4.5 million in Q3 2022.
- Average Research & Development over 5 years is $10.0 million, with a median of $9.4 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Research & Development jumped 239.05% in 2023, then plunged 46.76% in 2024.
- Over 5 years, Research & Development stood at $5.0 million in 2022, then jumped by 157.82% to $12.8 million in 2023, then advanced by 28.42% to $16.5 million in 2024, then advanced by 2.84% to $16.9 million in 2025, then gained by 1.42% to $17.2 million in 2026.
- The last three Research & Development figures came in at $17.2 million (Q2 2026), $12.6 million (Q1 2026), and $16.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 2.81 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -2.60 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | 394.92 Mn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 516.95 Mn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | 146.30 Mn |
| 10 | Liquidia | 6.09 Bn | 5.81 Bn | 160.92 Mn | 17.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.18 Mn |
| Mar 31, 2026 | 12.57 Mn |
| Dec 31, 2025 | 16.94 Mn |
| Sep 30, 2025 | 9.35 Mn |
| Jun 30, 2025 | 6.02 Mn |
| Mar 31, 2025 | 6.97 Mn |
| Dec 31, 2024 | 16.48 Mn |
| Sep 30, 2024 | 11.89 Mn |
| Jun 30, 2024 | 9.42 Mn |
| Mar 31, 2024 | 10.06 Mn |
| Dec 31, 2023 | 12.83 Mn |
| Sep 30, 2023 | 7.44 Mn |
| Jun 30, 2023 | 17.70 Mn |
| Mar 31, 2023 | 5.28 Mn |
| Dec 31, 2022 | 4.98 Mn |
| Sep 30, 2022 | 4.51 Mn |
| Jun 30, 2022 | 5.22 Mn |
| Mar 31, 2022 | 4.73 Mn |
| Dec 31, 2021 | 5.38 Mn |
| Sep 30, 2021 | 4.49 Mn |